Oxazole-Based Compounds As Anticancer Agents
Maria Assunta ChiacchioDipartimento di Scienze del Farmaco, University of Catania, V.le Doria 6, 95125 Catania, ItalyGiuseppe LanzaDipartimento di Scienze del Farmaco, University of Catania, V.le Doria 6, 95125 Catania, ItalyUgo ChiacchioDipartimento di Scienze del Farmaco, University of Catania, V.le Doria 6, 95125 Catania, ItalySalvatore V. GiofrèDipartimento di Scienze Chimiche, Biologiche, Farmaceutiche e Ambientali, University of Messina, Via S.S. Annunziata, 98168 Messina, ItalyRoberto RomeoDipartimento di Scienze Chimiche, Biologiche, Farmaceutiche e Ambientali, University of Messina, Via S.S. Annunziata, 98168 Messina, ItalyDaniela IannazzoDipartimento di Ingegneria, University of Messina, Contrada Di Dio, 98166 Messina, ItalyLaura LegnaniDipartimento di Scienze del Farmaco, University of Catania, V.le Doria 6, 95125 Catania, Italy
2018en
ABI
Аннотация
Heterocyclic compounds represent a significant target for anti-cancer research and drug discovery, due to their structural and chemical diversity. Oxazoles, with oxygen and nitrogen atoms present in the core structure, enable various types of interactions with different enzymes and receptors, favoring the discovery of new drugs. Aim of this review is to describe the most recent reports on the use of oxazole-based compounds in anticancer research, with reference to the newly discovered iso/oxazole-based drugs, to their synthesis and to the evaluation of the most biologically active derivatives. The corresponding dehydrogenated derivatives, i.e. iso/oxazolines and iso/oxazolidines, are also reported.
Перевод пока недоступен
Идентификаторы
Цитирования и источники
Цитирований: 3Использованных источников: 0